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Abstract: 
The objective of the present study is optimization of valsartan floating tablet formulation by 23 factorial design. Floating tablets 
of valsartan (80 mg) were formulated employing Cross linked starch-urea, a new modified starch (50 %) as matrix forming 
polymer, sodium bicarbonate as gas generating agent and beeswax and starch acetate as floating enhancers. Valsartan is an 
orally active anti-hypertensive drug, majorly absorbed from stomach and upper small intestine. Formulation of sustained release 
floating tablets of valsartan is needed because of its poor oral bioavailability and short biological half-life. Valsartan floating 
tablets were formulated as per 23 factorial design and were evaluated.  
The individual effects of sodium bicarbonate (Factor A) and starch acetate (Factor C) and their combined effect (AC) on the 
floating lag time were significant (P < 0.05).Whereas the individual effect of bees wax (Factor B) and all other combined effects 
of  the three factors involved were not significant in influencing floating lag time of the tablets. Formulations Fa, Fab, Fac and Fabc 
exhibited excellent floating over more than 12 h with a floating lag time in the range 12-40 seconds. Higher levels (20 %) of 
sodium bicarbonate gave shorter floating lag time. Valsartan release from the floating tablets prepared except formulation Fa 
was slow and spread over 12 h and dependent on the composition of the tablets. Drug release from formulation Fa was very 
rapid. Valsartan release from the floating tablets was by non-fickian diffusion mechanism in all the cases except Fa. In the case 
of formulation Fa that gave rapid release of drug fickian diffusion was the drug release mechanism. 
Optimization of valsartan floating tablet formulation was done taking floating lag time as the parameter for optimization. The 
polynomial equation describing the relationship between the response, Y  and the variables, X1 , X 2 and X3 based on the observed 
data was found to be Y = 8.996  - 8.596 (X1) + 2.396 (X2) – 2.431 (X1 X2) + 0.561 (X3) - 0.521 (X1 X3) + 0.396 (X2 X3) - 0.271 
(X1 X2 X3).Based on the  polynomial equation developed, the optimized valsartan floating tablet formulation with a floating lag 
time of 20 seconds could be formulated employing sodium bicarbonate (160mg/tablet), beeswax (28mg/tablet) and starch acetate 
(10mg/tablet). The optimized formulation (Fopt) exhibited a floating time of 12-14 h with a lag time of 21 seconds fulfilling the 
target floating lag time set indicating validity of the optimization technique employed.  
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INTRODUCTION: 
Oral drug delivery is the most desirable and preferred 
method of administering therapeutic agents for their 
systemic effects. The high level of patient 
compliance in taking oral dosage forms is due to the 
ease of administration, patient compliance, flexibility 
in formulation and handling of these forms [1]. 
However the oral route of administration suffers with 
certain limitations such as short residence time of the 
dosage form in the g.i. tract, unpredictable gastric 
emptying, degradation of the drug due to highly 
reactive nature of g.i. contents and existence of an 
absorption window in the gastric and upper small 
intestine for several drugs. Gastric emptying is a 
complex process and makes in vivo performance of 
the drug delivery system uncertain. Formulation of 
floating drug delivery systems is a useful approach to 
avoid this variability with increased gastric retention 
time of the drug delivery system. Floating systems or 
hydrodynamically controlled systems are low-density 
systems that have sufficient buoyancy to float over 
the gastric contents and remain buoyant in the 
stomach for a prolonged period of time .While the 
system is floating on the gastric contents, the drug is 
released slowly at the desired rate from the system. 
After release of drug, the residual system is emptied 
from the stomach .This results in an increased gastric 
residence time and a better control of the fluctuation 
in plasma drug concentration [2], [3]. Several 
approaches are currently used to retain the dosage in 
the stomach. These include bioadhesive systems, 
swelling and expanding systems ,floating systems 
and other delayed gastric emptying devices[4,5]. 
The principle of floating tablets offers a simple and 
practical approach to achieve increased residence 
time in the stomach and upper g.i. tract to enhance 
the bioavailability and to obtain controlled release. 
Floating tablets are designed based on gas generating 
principle. Design of floating tablets needs a strong 
matrix forming polymer, a gas generating agent and a 
floating enhancer such as beeswax. Several polymers 
such as various viscosity grades of HPMC, Carbopol 
934P, Eudragit RL, calcium alginate, Chitosan, 
Xanthan gum, guargum, etc., have been used in the 
design of floating tablets of various API. Sodium 
bicarbonate is the preferred gas generating agent in 
the formulation of floating tablets. 
In the present study sustained release floating tablets 
of valsartan were formulated employing Cross linked 
starch-urea, a new modified starch (50 %) as matrix 
forming polymer, sodium bicarbonate as gas 
generating agent and beeswax and starch acetate as 
floating enhancers. Valsartan is an angiotensin 
receptor blocker widely prescribed for hypertension. 
It is absorbed from stomach and upper small 
intestine[6,7] . The oral bioavailability of valsartan 
was 23 %. It has a short biological half life of 3-6 
hrs[8]. Hence sustained release floating tablet 
formulation is needed for valsartan to enhance its oral 
bioavailability and to prolong its therapeutic effect, to 
reduce dosage frequency and to increase patient 
compliance. 
 Floating tablets of valsartan were designed in the 
present study to enhance its bioavailability and to 
achieve sustained release over 12 h for b.i.d. 
administration. Sustained release of valsartan over 
12h is aimed in addition to good floating 
characteristics. Formulation of valsartan floating 
tablets was optimized by 23 factorial design. 
Optimization[9] of pharmaceutical formulations 
involves choosing and combining ingredients that 
will result in a formulation whose attributes confirm 
with certain prerequisite requirements. The choice of 
the nature and qualities of additives (excipients) to be 
used in a new formulation shall be on a rational basis. 
The application of formulation optimization 
techniques is relatively new to the practice of 
pharmacy. In general the procedure consists of 
preparing a series of formulations, varying the 
concentrations of the formulation ingredients in some 
systematic manner. These formulations are then 
evaluated according to one or more attributes, such as 
hardness, dissolution, appearance, stability, taste and 
so on. Based on the results of these tests, a particular 
formulation (or series of formulations) may be 
predicted to be optimal. The optimization procedure 
is facilitated by applying factorial designs and by the 
fitting of an empirical polynomial equation to the 
experimental results. The predicted optimal 
formulation has to be prepared and evaluated to 
confirm its quality. The objective of the present study 
is optimization of valsartan floating tablet 
formulation by 23 factorial design. 
 
MATERIALS AND METHODS: 
Materials 
Valsartan was a gift sample from M/s Micro Labs 
Ltd, Pondicherry. Cross linked starch-urea was 
prepared in the laboratory. Starch acetate (50 cps), 
sodium bicarbonate, Lactose and beeswax were 
procured from commercial sources. All other 
materials used were of Pharmacopoeial grade. 
Methods 
Preparation of Cross linked Starch - Urea 
Polymer [10] 
 Potato starch (9 parts) was dispersed in purified 
water (10 parts) to form starch slurry. Urea (1 part), 
calcium chloride (1 part) were dissolved in purified 
water (40 parts) and the solution was heated to 
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boiling. While boiling, the starch slurry was added 
and mixed. Mixing while heating was continued for 
20 minutes to form cross-linked starch-urea polymer. 
The mass formed was spread on to a stainless steel 
plate and dried at 85oC for 6-8 h. The dried polymer 
was powdered and passed through mesh No. 120.  
Formulation of Floating Tablets 
Matrix tablets each containing 80 mg of valsartan 
were formulated employing Cross linked starch- urea 
(50%) as matrix forming polymer, sodium 
bicarbonate as gas generating agent and starch acetate 
and beeswax as floating enhancers.  Valsartan 
floating tablets were formulated as per 23 factorial 
design. The three factors involved in the 23 factorial 
design are sodium bicarbonate (Factor A), beeswax 
(Factor B) and starch acetate (Factor C). The two 
levels of sodium bicarbonate (Factor A) are 10 % and 
20 %, the two levels of beeswax (Factor B) are 2 % 
and 5 % and the two levels of starch acetate (Factor 
C) are 5% and 10%. Eight valsartan floating tablet 
formulations were prepared employing selected 
combinations of the levels of the three factors as per 
23 factorial design. The floating tablets were prepared 
by melting- wet granulation method as per the 
formula given in Table 1. 
Table 1: Formulae of Valsartan Floating Tablets Prepared as Per 23 Factorial Design and Optimized 
Formulation 
 
 
 
 
 
 
 
Ingredient (mg/tab) F (1) F (a) F (b) F (ab) F (c) F (ac) F (bc) F (abc) F 
(opt) 
Valsartan 80 80 80 80 80 80 80 80 80 
Sodium bicarbonate 80 160 80 160 80 160 80 160 160 
Bees wax 16 16 40 40 16 16 40 40 28 
Starch acetate  40 40 40 40 80 80 80 80 10 
Cross linked Starch 
Urea  
400 400 400 400 400 400 400 400 400 
Lactose 164 84 140 60 124 44 100 20 102 
Talc 10 10 10 10 10 10 10 10 10 
Magnesium stearate 10 10 10 10 10 10 10 10 10 
Total weight (mg) 800 800 800 800 800 800 800 800 800 
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The required quantities of valsartan, Cross linked 
starch-urea, starch acetate, lactose and sodium 
bicarbonate were thoroughly mixed in a dry mortar 
by following geometric dilution technique. Beeswax 
was melted in a dry beaker and the blend of the above 
mentioned ingredients was added to the molten 
beeswax and mixed thoroughly.  The blend was 
transferred to a dry mortar and granulated with 
hydro-alcoholic (1:1) solution. The dried granules 
formed were passed through mesh No. 16 to break 
the aggregates. The lubricants talc and magnesium 
stearate were passed through mesh No. 60 on to the 
dry granules and blended in a closed polyethylene 
bag. The tablet granules were then compressed into 
800mg tablets on a 8-station tablet punching machine 
(Karnavathi Rimek Minipress II) to a hardness of 4-5 
Kg/cm2.  
Evaluation of Tablets  
Hardness of the tablets was tested using a Monsanto 
hardness tester. Friability of the tablets was 
determined in a Roche friabilator. Disintegration time 
of the tablets was determined using a Paramount 
tablet disintegration test machine using water, 0.1N 
HCl and phosphate buffer of pH 7.4 as the test fluids. 
Estimation of Valsartan 
An ultraviolet (UV) spectrophotometric method 
based on the measurement of absorbance at 250 nm 
in 0.1N HCl was used for the estimation of valsartan. 
The method obeyed Beer-Lambert’s law in the 
concentration range of 0-10 μg / mL. When a 
standard drug solution was assayed repeatedly (n=6), 
the relative error (accuracy) and coefficient of 
variation (precision) were found to be 0.75% and 
1.45% respectively. No interference from the 
excipients used was observed. 
Floating Lag Time and Floating Time 
In Vitro buoyancy was determined by 
measuring floating lag time and duration of floating. 
The tablets were placed in a 250 ml glass beaker 
containing 0.1N HCl. The time required for the tablet 
to rise to the surface and float was determined as 
floating lag time. The duration in which the tablet 
remains floating was determined as floating time. 
Drug Release Study                                                                                                                   
Drug release from the floating tablets prepared was 
studied using 8-station dissolution rate test apparatus 
(Labindia, DS 8000) employing a paddle stirrer at 50 
rpm and at a temperature of 37±1⁰C. Hydrochloric 
acid, 0.1 N (900 mL) was used as dissolution fluid. A 
5mL aliquot of dissolution medium was withdrawn 
through a filter (0.45μm) at different time intervals 
and assayed spectrophotometrically by measuring 
absorbance at 250 nm. All drug release experiments 
were conducted in triplicate (n=3). 
Data Analysis 
Drug release data were analysed as per Zero order, 
first order, Higuichi[11] and Korsemeyer - Peppas[12] 
equation models to assess drug release kinetics and 
mechanism from the floating tablets prepared. 
 RESULTS AND DISCUSSION: 
 The principle of floating tablets offers a simple and 
practical approach to achieve increased residence 
time in the stomach and upper G.I. tract to enhance 
the bioavailability and to obtain controlled release. 
Floating tablets of valsartan were designed based on 
gas generating principle. The objective of the present 
study is formulation development and optimization of 
valsartan floating tablets based on gas generating 
principle.   
Matrix tablets each containing 80 mg of valsartan 
were formulated employing Cross linked starch- urea 
(50%) as matrix forming polymer, sodium 
bicarbonate as gas generating agent and starch acetate 
and beeswax as floating enhancers. Valsartan floating 
tablets were formulated as per 23 factorial design. 
The three factors involved in the 23 factorial study are 
sodium bicarbonate (Factor A), beeswax (Factor B) 
and starch acetate (Factor C). The two levels of 
sodium bicarbonate (Factor A) are 10 % and 20 %, 
the two levels of beeswax (Factor B) are 2 % and 5 % 
and the two levels of starch acetate (Factor C) are 5% 
and 10%. Eight valsartan   floating tablet 
formulations were prepared employing selected 
combinations of the levels of the three factors as per 
23 factorial design. The floating tablets were prepared 
by melting- wet granulation method as per the 
formula given in Table 1. All the floating tablets 
prepared were evaluated for drug content, hardness, 
friability, disintegration time, floating lag time, 
floating time and drug release characteristics. 
The physical parameters of the floating tablets 
prepared are given in Table 2.  
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Table 2: Physical Parameters of Valsartan Floating Tablets Prepared as per 23 Factorial Design and 
Optimized Formulation 
Formulation Hardness 
(Kg/cm2) 
Friability 
(% wt. loss) 
Drug Content 
(mg/tablet) 
Floating lag 
time 
(min- sec) 
Floating Time 
(h) 
F 1 4.5 0.65 79.60 12-30 >12 
F a 5.5 0.45 80.05 0-40 >12 
F b 5.0 0.58 80.25 20-40 >12 
F ab 4.5 0.30 80.15 0-12 >12 
F c 5.5 0.45 79.20 13-20 >12 
F ac 5.5 0.48 79.45 0-30 >12 
F bc 5.0 0.72 79.80 24-10 >12 
F abc 4.5 0.45 80.20 0-32 >12 
F opt 5.5 0.60 80.15 0-21 >12 
 
Hardness of the tablets was in the range 4.5-5.5 
Kg/cm2.Weight loss in the friability test was in the 
range of 0.35 % – 0.72 % in all the cases. All the 
tablets prepared contained valsartan within 100±2% 
of the labelled claim.  All the floating tablets 
prepared were found to be non-disintegrating in water 
and aqueous acidic (pH 1.2) and alkaline (pH 7.4) 
fluids. As such the prepared floating tablets were of 
good quality with regard to drug content, hardness, 
friability and were suitable for controlled release.  
In the in vitro buoyancy study, the floating lag time 
of various tablets was in the range 12 seconds to 
24.17 minutes. Floating time of all the tablets 
prepared was more than 12 hours. The floating lag 
time values were subjected to ANOVA to find out the 
significance of the individual and combined effects of 
the three factors, sodium bicarbonate, beeswax and 
starch acetate on the floating characteristics of the 
tablets prepared. The results of ANOVA indicated 
that the individual effects of sodium bicarbonate 
(Factor A) and starch acetate (Factor C) and their 
combined effect (AC) on the floating lag time are 
significant (P < 0.05).Whereas the individual effect 
of bees wax (Factor B) and all other combined effects 
of the three factors involved are not significant in 
influencing floating lag time of the tablets. 
The order of increasing floating lag time observed 
with various floating tablets prepared was Fab < Fac < 
Fabc< Fa< F1 < Fc< Fb < Fbc. Formulations  Fa, Fab, Fac 
and Fabc exhibited excellent floating over 12-14 h 
with a floating lag time in the range 12-40 seconds.  
Sodium bicarbonate at 20 % strength gave less 
floating lag time than at 10 % strength.  Formulations 
Fa, Fab, Fac and Fabc are considered as the best floating 
tablets formulated based on the floating 
characteristics.  
Valsartan release from the floating tablets formulated 
was studied in 0.1 N hydrochloric acid. Drug release 
parameters of the tablets prepared are summarized in 
Table 4. Valsartan release from the floating tablets 
prepared was slow and spread over 12 - 14 h and 
depended on the composition of the tablets. The 
release data were analyzed as per zero order, first 
order, Higuchi and Korsemeyer- Peppas kinetic 
models. The correlation coefficient (r) values in the 
analysis of release data as per different kinetic 
models are given in Table 3. The drug release plots 
are shown in Figs 1 – 2.  
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Drug release from all the floating tablets prepared 
was diffusion controlled as indicated by the linear 
Higuchi plots. When the release data were analyzed 
as per Korsemeyer- Peppas equation, the release 
exponent ‘n’ was found to be in the range 0.51 - 0.63 
in all the cases except formulation  Fa   indicating 
‘non-Fickian diffusion’ as the release mechanism 
from these floating tablets. In the case of formulation 
Fa, that gave rapid release of drug, the release 
exponent ‘n’ was found to be 0.10  indicating fickian 
diffusion as the drug release mechanism. 
 
Table 3: Correlation Coefficient (r) values in the analysis of Release data of Floating Tablets of Valsartan as 
per various Kinetic models 
 
Formulation Zero  
Order 
First  
Order 
Higuchi Korsemeyer - 
Peppas 
F 1 0.9272 0.9726 0.9978 0.9955 
F a 0.492 0.9808 0.9878 0.9818 
F b 0.9582 0.9612 0.9936 0.9928 
F ab 0.9497 0.9673 0.9978 0.9978 
F c 0.9328 0.9837 0.9928 0.9879 
F ac 0.9793 0.9758 0.9810 0.9898 
F bc 0.9558 0.9873 0.9923 0.9905 
F abc 0.9570 0.9487 0.9869 0.9792 
F opt 0.9609 0.9407 0.9932 0.9964 
 
Table: 4 Release Parameters of Valsartan Floating Tablets Prepared as per 23 Factorial Design and 
Optimized Formulation 
 
Formulation T50 
(h) 
Release Rate Release Exponent 
(n) 
K0  (mg/h) K1(h-1) 
F 1 3.1 8.32 0.2513 0.51 
F a 0.36 18.22 1.9455 0.10 
F b 4.6 6.79 0.1554 0.55 
F ab 3.9 7.32   0.1920 0.52 
F c 3.8 7.71 0.1812 0.57 
F ac 6.4 6.56 0.1283 0.63 
F bc 4.6 7.24 0.1505 0.61 
F abc 5.7 6.31 0.1392 0.53 
Fopt 4.5 6.88 0.1810 0.58 
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Fig. 1: Drug Release Profiles of Valsartan Floating Tablets  Prepared (F1 , Fa, Fb, Fab) 
 
Fig.2: Drug Release Profiles of Valsartan Floating Tablets  Prepared (Fc ,Fac, Fbc, Fabc) and optimized 
formulation (Fopt) 
 
Optimization: 
Optimization of valsartan floating tablet formulation 
was done taking floating lag time as the parameter for 
optimization. For optimization, floating lag time was 
taken as response (Y) and level of sodium 
bicarbonate as (X1), level of bees wax as (X2) and 
level of starch acetate as (X3). The polynomial 
equation describing the relationship between the 
response, Y and the variables, X1, X 2 and X3 based on 
the observed data was found to be  
Y = 8.996  - 8.596 (X1) + 2.396 (X2) – 2.431 (X1 
X2) + 0.561 (X3) - 0.521 (X1 X3) + 0.396 (X2 X3) - 
0.271 (X1 X2 X3). 
The magnitude of the coefficients of the variables in 
the polynomial equation indicate the relative strength 
of the variables in influencing the response involved. 
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In the above polynomial equation, the coefficients of 
variables X1 (sodium bicarbonate) is much higher 
when compared to the coefficients of other variables. 
As such the results indicate that the floating lag time 
is much influenced by the sodium bicarbonate levels 
in the formulation. 
Based on the above polynomial equation, the 
optimized valsartan floating tablet formulation with a 
floating lag time of 20 seconds or 0.33 min could be 
formulated employing sodium bicarbonate (160 
mg/tablet), beeswax (28 mg/tablet) and starch acetate 
(10 mg/tablet). To verify valsartan floating tablets 
were formulated employing the optimized levels of 
sodium bicarbonate, beeswax and starch acetate as 
per the formula given in Table 1. The optimized 
valsartan floating tablet formulation was prepared 
and evaluated for floating and drug release 
characteristics. The optimized formulation exhibited 
a floating time of 14 h with a lag time of 21 seconds 
fulfilling the target floating lag time set. This result 
also indicated validity of the optimization technique 
employed. The optimized formulation exhibited a 
slow release of Valsartan over 12h. 
Overall, formulations Fopt and Fab prepared exhibited 
excellent floating characteristics (floating over 13-14 
h with a lag time of 21 and 12 seconds respectively) 
and good sustained release of valsartan over 12 . As 
such, formulations Fopt and Fab are considered as the 
best floating tablet formulations of valsartan suitable 
for b.i.d administration.  
 
CONCLUSIONS: 
1.  Valsartan  floating tablets prepared as per 23 
factorial design were non-disintegrating in  water  
and aqueous acidic (pH 1.2) and alkaline (pH 7.4) 
fluids and were of good quality with regard to drug 
content, hardness, friability and suitable for 
controlled release. 
2. The individual effects of sodium bicarbonate 
(Factor A) and starch acetate (Factor C) and their 
combined effect (AC) on the floating lag time were 
significant (P < 0.05).Whereas the individual effect 
of bees wax (Factor B) and all other combined effects 
of  the three factors involved were not significant in 
influencing floating lag time of the tablets. 
3. Formulations Fa, Fab, Fac and Fabc exhibited 
excellent floating over >12 h with a floating lag time 
in the range 12-40 seconds. Higher levels (20 %) of 
sodium bicarbonate gave shorter floating lag time.   
4. Valsartan release from the floating tablets prepared 
except formulation Fa was slow and spread over 12 h 
and dependent on the composition of the tablets.  
Drug release from formulation Fa was very rapid. 
5. Valsartan release from the floating tablets was by 
non-fickian diffusion mechanism in all the cases 
except Fa. In the case of formulation Fa that gave 
rapid release of drug fickian diffusion was the drug 
release mechanism. 
6. Optimization of valsartan floating tablet 
formulation was done taking floating lag time as the 
parameter for optimization. For optimization, floating 
lag time was taken as response (Y) and level of 
sodium bicarbonate as (X1), level of bees wax as (X2) 
and level of starch acetate as (X3).  
7. The polynomial equation describing the 
relationship between the response, Y  and the 
variables, X1 , X 2 and X3 based on the observed data 
was found to be Y = 8.996  - 8.596 (X1) + 2.396 (X2) 
– 2.431 (X1 X2) + 0.561 (X3) - 0.521 (X1 X3) + 
0.396 (X2 X3) - 0.271 (X1 X2 X3). 
8. Based on the  polynomial equation developed, the 
optimized valsartan floating tablet formulation with a 
floating lag time of 20 seconds could be formulated 
employing sodium bicarbonate (160mg/tablet), 
beeswax (28mg/tablet) and starch acetate 
(10mg/tablet). 
9. The optimized formulation (Fopt) exhibited a 
floating time of 12-14 h with a lag time of 21 seconds 
fulfilling the target floating lag time set indicating 
validity of the optimization technique employed. 
10. Formulations Fopt and Fab prepared exhibited 
excellent floating characteristics (floating over 12 
with a lag time of 21 and 12seconds respectively) and 
good sustained release of valsartan over 12– 14h.  
11. Formulations Fopt and Fab are considered as the 
best floating tablet formulations of valsartan suitable 
for b.i.d administration.  
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